CRNX
Crinetics Pharmaceuticals, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+166.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CRNX vs CHRS vs RCUS vs ESPR
Revenue, margins, valuation, and 5-year total return — side by side.
CHRS
Coherus Oncology, Inc.
Biotechnology
Market Cap$213M
5Y Perf.-90.6%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-20.9%
ESPR
Esperion Therapeutics, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$653M
5Y Perf.-92.6%
CRNX vs CHRS vs RCUS vs ESPR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CRNX | CHRS | RCUS | ESPR |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.55B | $213M | $2.50B | $653M |
| Revenue (TTM) | $16M | $42M | $236M | $403M |
| Net Income (TTM) | $-496M | $168M | $-369M | $-23M |
| Gross Margin | 101.6% | -37.3% | 90.7% | 64.4% |
| Operating Margin | -34.6% | -429.5% | -168.6% | 15.0% |
| Forward P/E | — | 1.2x | — | — |
| Total Debt | $49M | $1M | $99M | $548M |
| Cash & Equiv. | $102M | $89M | $222M | $168M |
CRNX vs CHRS vs RCUS vs ESPR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRNX
CHRS
RCUS
ESPR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Crinetics Pharmaceu… (CRNX) | 100 | 266.1 | +166.1% |
| Coherus Oncology, I… (CHRS) | 100 | 9.4 | -90.6% |
| Arcus Biosciences, … (RCUS) | 100 | 79.1 | -20.9% |
| Esperion Therapeuti… (ESPR) | 100 | 7.4 | -92.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRNX vs CHRS vs RCUS vs ESPR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRNX and CHRS are tied at the top with 2 categories each — the right choice depends on your priorities. Coherus Oncology, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. ESPR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CRNX
Crinetics Pharmaceuticals, Inc.
The Income Pick
CRNX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.36
- 77.4% 10Y total return vs RCUS's 45.9%
- Lower volatility, beta 1.36, Low D/E 4.9%, current ratio 12.32x
- Beta 1.36, current ratio 12.32x
Best for: income & stability and long-term compounding
CHRS
Coherus Oncology, Inc.
The Quality Compounder
CHRS is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 398.4% margin vs CRNX's -31.4%
- 42.4% ROA vs CRNX's -39.5%
Best for: quality and efficiency
RCUS
Arcus Biosciences, Inc.
The Secondary Option
RCUS lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
ESPR
Esperion Therapeutics, Inc.
The Growth Play
ESPR is the clearest fit if your priority is growth exposure.
- Rev growth 21.3%, EPS growth 60.7%, 3Y rev CAGR 74.8%
- +260.5% vs CRNX's +38.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRNX | 6.4% revenue growth vs CHRS's -84.2% |
| Quality / Margins | CHRS | 398.4% margin vs CRNX's -31.4% |
| Stability / Safety | CRNX | Beta 1.36 vs ESPR's 2.33 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ESPR | +260.5% vs CRNX's +38.5% |
| Efficiency (ROA) | CHRS | 42.4% ROA vs CRNX's -39.5% |
CRNX vs CHRS vs RCUS vs ESPR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
CRNX vs CHRS vs RCUS vs ESPR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLESPRLAGGINGRCUS
Who Leads Where
ESPR leads in 3 of 6 categories
CHRS leads 1 • CRNX leads 0 • RCUS leads 0 • 1 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
CRNXCrinetics Pharmaceuti…
0leads
CHRSCoherus Oncology, Inc.
1leads
ESPREsperion Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs CHRSvs CRNXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ESPR3/6
Valuation MetricsMultiples, price ratios, and targets
ESPR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CHRS5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ESPR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ESPR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ESPR is the larger business by revenue, generating $403M annually — 25.5x CRNX's $16M. CHRS is the more profitable business, keeping 4.0% of every revenue dollar as net income compared to CRNX's -31.4%. On growth, CRNX holds the edge at +28.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $16M | $42M | $236M | $403M |
| EBITDAEarnings before interest/tax | -$543M | -$184M | -$391M | $60M |
| Net IncomeAfter-tax profit | -$496M | $168M | -$369M | -$23M |
| Free Cash FlowCash after capex | -$420M | -$139M | -$489M | -$13M |
| Gross MarginGross profit ÷ Revenue | +101.6% | -37.3% | +90.7% | +64.4% |
| Operating MarginEBIT ÷ Revenue | -34.6% | -4.3% | -168.6% | +15.0% |
| Net MarginNet income ÷ Revenue | -31.4% | +4.0% | -156.4% | -5.6% |
| FCF MarginFCF ÷ Revenue | -26.6% | -3.3% | -2.1% | -3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.7% | -76.5% | -39.3% | +143.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -18.3% | +29.5% | +10.5% | +3.0% |
ESPR leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
ESPR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| Market CapShares × price | $4.6B | $213M | $2.5B | $653M |
| Enterprise ValueMkt cap + debt − cash | $4.5B | $126M | $2.4B | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | -8.78x | 1.23x | -7.54x | -28.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 17.11x |
| Price / SalesMarket cap ÷ Revenue | 591.48x | 5.06x | 10.11x | 1.62x |
| Price / BookPrice ÷ Book value/share | 4.12x | 3.47x | 4.22x | — |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
ESPR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CHRS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CHRS delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-69 for RCUS. CHRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), CHRS scores 4/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -44.0% | +7.9% | -69.0% | — |
| ROA (TTM)Return on assets | -39.5% | +42.4% | -35.3% | -6.0% |
| ROICReturn on invested capital | -37.8% | — | -64.1% | +66.5% |
| ROCEReturn on capital employed | -42.6% | -127.8% | -42.1% | +45.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 0 | 3 |
| Debt / EquityFinancial leverage | 0.05x | 0.02x | 0.16x | — |
| Net DebtTotal debt minus cash | -$53M | -$87M | -$123M | $380M |
| Cash & Equiv.Liquid assets | $102M | $89M | $222M | $168M |
| Total DebtShort + long-term debt | $49M | $1M | $99M | $548M |
| Interest CoverageEBIT ÷ Interest expense | — | -28.88x | -13.38x | 0.74x |
CHRS leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ESPR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRNX five years ago would be worth $25,634 today (with dividends reinvested), compared to $1,229 for CHRS. Over the past 12 months, ESPR leads with a +260.5% total return vs CRNX's +38.5%. The 3-year compound annual growth rate (CAGR) favors ESPR at 32.5% vs CHRS's -40.0% — a key indicator of consistent wealth creation.
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.0% | +28.5% | +6.5% | -15.4% |
| 1-Year ReturnPast 12 months | +38.5% | +86.0% | +209.6% | +260.5% |
| 3-Year ReturnCumulative with dividends | +97.3% | -78.4% | +24.9% | +132.6% |
| 5-Year ReturnCumulative with dividends | +156.3% | -87.7% | -18.6% | -85.9% |
| 10-Year ReturnCumulative with dividends | +77.4% | -90.8% | +45.9% | -79.6% |
| CAGR (3Y)Annualised 3-year return | +25.4% | -40.0% | +7.7% | +32.5% |
ESPR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CRNX and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CRNX is the less volatile stock with a 1.36 beta — it tends to amplify market swings less than ESPR's 2.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 86.3% from its 52-week high vs CHRS's 67.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 2.29x | 1.95x | 2.33x |
| 52-Week HighHighest price in past year | $57.99 | $2.62 | $28.72 | $4.18 |
| 52-Week LowLowest price in past year | $25.83 | $0.71 | $7.06 | $0.69 |
| % of 52W HighCurrent price vs 52-week peak | +75.0% | +67.3% | +86.3% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 62.6 | 48.5 | 60.5 | 73.0 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.1M | 1.2M | 11.5M |
Evenly matched — CRNX and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CRNX as "Buy", CHRS as "Buy", RCUS as "Buy", ESPR as "Hold". Consensus price targets imply 242.0% upside for CHRS (target: $6) vs 0.6% for ESPR (target: $3).
| Metric | CRNXCrinetics Pharmac… | CHRSCoherus Oncology,… | RCUSArcus Biosciences… | ESPREsperion Therapeu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $86.60 | $6.02 | $30.00 | $3.16 |
| # AnalystsCovering analysts | 18 | 16 | 18 | 25 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ESPR leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CHRS leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallEsperion Therapeutics, Inc. (ESPR)Leads 3 of 6 categories
Loading custom metrics...
CRNX vs CHRS vs RCUS vs ESPR: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is CRNX or CHRS or RCUS or ESPR a better buy right now?
For growth investors, Crinetics Pharmaceuticals, Inc.
(CRNX) is the stronger pick with 640. 7% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Crinetics Pharmaceuticals, Inc. (CRNX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRNX or CHRS or RCUS or ESPR?
Over the past 5 years, Crinetics Pharmaceuticals, Inc.
(CRNX) delivered a total return of +156. 3%, compared to -87. 7% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: CRNX returned +77. 4% versus CHRS's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRNX or CHRS or RCUS or ESPR?
By beta (market sensitivity over 5 years), Crinetics Pharmaceuticals, Inc.
(CRNX) is the lower-risk stock at 1. 36β versus Esperion Therapeutics, Inc. 's 2. 33β — meaning ESPR is approximately 71% more volatile than CRNX relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRNX or CHRS or RCUS or ESPR?
By revenue growth (latest reported year), Crinetics Pharmaceuticals, Inc.
(CRNX) is pulling ahead at 640. 7% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -34. 1% for Crinetics Pharmaceuticals, Inc.. Over a 3-year CAGR, ESPR leads at 74. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRNX or CHRS or RCUS or ESPR?
Coherus Oncology, Inc.
(CHRS) is the more profitable company, earning 398. 4% net margin versus -60. 5% for Crinetics Pharmaceuticals, Inc. — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ESPR leads at 15. 0% versus -67. 1% for CRNX. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CRNX or CHRS or RCUS or ESPR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CRNX or CHRS or RCUS or ESPR better for a retirement portfolio?
For long-horizon retirement investors, Crinetics Pharmaceuticals, Inc.
(CRNX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRNX: +77. 4%, CHRS: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRNX and CHRS and RCUS and ESPR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CRNX is a small-cap high-growth stock; CHRS is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock; ESPR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(CRNX: 2873.4% · CHRS: -76.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.